These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 21107315)
21. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Tremollieres F; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Vujovic S; Rozenberg S; Rees M; Maturitas; 2011 Jun; 69(2):195-8. PubMed ID: 21489728 [TBL] [Abstract][Full Text] [Related]
23. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Rosendaal FR; Psaty BM Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2807-12. PubMed ID: 16973976 [TBL] [Abstract][Full Text] [Related]
24. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Canonico M Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103 [TBL] [Abstract][Full Text] [Related]
25. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Canonico M; Scarabin PY Climacteric; 2009; 12 Suppl 1():76-80. PubMed ID: 19811247 [TBL] [Abstract][Full Text] [Related]
26. [Hormone therapy and risk of venous thromboembolism: new insights from the ESTHER study]. Canonico M; Scarabin PY Med Sci (Paris); 2008 Mar; 24(3):228-31. PubMed ID: 18334161 [No Abstract] [Full Text] [Related]
27. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706 [TBL] [Abstract][Full Text] [Related]
29. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Scarabin PY Climacteric; 2018 Aug; 21(4):341-345. PubMed ID: 29570359 [TBL] [Abstract][Full Text] [Related]
30. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration. Połać I; Borowiecka M; Wilamowska A; Nowak P Gynecol Endocrinol; 2013 Feb; 29(2):165-8. PubMed ID: 23116237 [TBL] [Abstract][Full Text] [Related]
31. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312 [TBL] [Abstract][Full Text] [Related]
32. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Jick SS; Kaye JA; Russmann S; Jick H Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560 [TBL] [Abstract][Full Text] [Related]
33. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Laliberté F; Dea K; Duh MS; Kahler KH; Rolli M; Lefebvre P Menopause; 2018 Nov; 25(11):1297-1305. PubMed ID: 30358726 [TBL] [Abstract][Full Text] [Related]
34. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Simon JA Climacteric; 2012 Apr; 15 Suppl 1():3-10. PubMed ID: 22432810 [TBL] [Abstract][Full Text] [Related]
35. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Høibraaten E; Qvigstad E; Arnesen H; Larsen S; Wickstrøm E; Sandset PM Thromb Haemost; 2000 Dec; 84(6):961-7. PubMed ID: 11154141 [TBL] [Abstract][Full Text] [Related]
36. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study. Fait T; Vrablik M; Zizka Z; Kostirova M Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346 [TBL] [Abstract][Full Text] [Related]
37. Venous thrombosis and conjugated equine estrogen in women without a uterus. Curb JD; Prentice RL; Bray PF; Langer RD; Van Horn L; Barnabei VM; Bloch MJ; Cyr MG; Gass M; Lepine L; Rodabough RJ; Sidney S; Uwaifo GI; Rosendaal FR Arch Intern Med; 2006 Apr; 166(7):772-80. PubMed ID: 16606815 [TBL] [Abstract][Full Text] [Related]